ANIP logo

ANI Pharmaceuticals Inc. (ANIP)

$69.99

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ANIP

Market cap

$1.59B

EPS

4.8

P/E ratio

15.6

Price to sales

1.73

Dividend yield

--

Beta

0.451969

Price on ANIP

Previous close

$70.89

Today's open

$69.98

Day's range

$69.75 - $70.93

52 week range

$67.14 - $87.76

Profile about ANIP

CEO

Nikhil Lalwani

Employees

970

Headquarters

Princeton, NJ

Exchange

NASDAQ Global Market

Shares outstanding

22718931

Issue type

Common Stock

ANIP industries and sectors

Healthcare

Pharmaceuticals

News on ANIP

Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

news source

Zacks Investment Research • Nov 17, 2026

news preview

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao - Chief Medical Officer Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Yuchen Ding - Jefferies LLC, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Gary Nachman - Canaccord Genuity Corp., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. Third Quarter 2026 Earnings Results Conference Call.

news source

Seeking Alpha • Nov 7, 2026

news preview

ANI Pharmaceuticals Q3 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outlook for Cortrophin Gel after pharmacy bottlenecks slowed the conversion of new patient cases into treatment.

news source

MarketBeat • Nov 5, 2026

news preview

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).

news source

GlobeNewsWire • Nov 5, 2026

news preview

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).

news source

GlobeNewsWire • Nov 5, 2026

news preview

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 5, 2026

news preview

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:

news source

GlobeNewsWire • Nov 3, 2026

news preview

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.

news source

GlobeNewsWire • Oct 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in ANI Pharmaceuticals Inc.

Open an M1 investment account to buy and sell ANI Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ANIP on M1